4-tert-Butylpyridazine | 194865-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-tert-Butylpyridazine
• CAS: 194865-86-6
• 化学式: C₈H₁₂N₂
• 分子量: 136.197
• InChiKey: OQSCERIJWXIDGD-UHFFFAOYSA-N

物化性质

• 沸点：
  235.2±9.0 °C(Predicted)
• 密度：
  0.955±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  三甲基氰硅烷 、 4-tert-Butylpyridazine 在 aluminum (III) chloride 、 对甲苯磺酰氯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 反应 51.0h， 以65%的产率得到5-tert-butylpyridazine-3-carbonitrile
  参考文献：
  名称：

  Efficient synthesis of 5-substituted-3-pyridazine carbonitrile via regioselective Reissert-type reaction

  摘要：

  Various 5-substituted-3-pyridazine carbonitrile derivatives were synthesized by regioselective Reissert-type reaction with 4-substituted pyridazine, 4-methylbenzene-1-sulfonyl chloride and trimethylsilyl cyanide. The reaction can be carried out under conditions of AlCl3 as catalyst, THF as solvent at 10 degrees C, followed by treatment with DBU which gave moderate yields and good regioselectivity. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2016.05.037
• 作为产物：
  描述：

  1,2,4,5-四嗪 、 3,3-二甲基-1-丁炔 反应 672.0h， 以74%的产率得到4-tert-Butylpyridazine
  参考文献：
  名称：

  Synthesis of metallated (metal = Si, Ge, Sn) pyridazines by cycloaddition of metal substituted alkynes to 1,2,4,5-tetrazine

  摘要：

  MR3-substituted alkynes 2 and 3 (M = Si, Ge, Sn; R = alkyl) show high reactivity in inverse-type Diels-Alder reactions with the R-electron-deficient 1,2,4,5-tetrazine 1 in strict contrast to the corresponding carbon compounds. Kinetic data prove the huge accelerating effect of the trialkyltin substituent, offering a simple access to new heteroaromatic organotin derivatives, which can be easily transformed by standard methods of organotin chemistry. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)01279-3

文献信息

• SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190224188A1

  公开（公告）日：2019-07-25

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式(I)的化合物及其药学上可接受的盐： 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Revolution Medicines, Inc.

  公开号：US20210139517A1

  公开（公告）日：2021-05-13

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS
  申请人：Melvin, JR. Lawrence S.

  公开号：US20100022543A1

  公开（公告）日：2010-01-28

  The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

  本发明提供了一种具有组蛋白去乙酰化酶（HDAC）抑制活性的一般式（I）化合物，包括该化合物的药物组合物，以及使用该化合物治疗疾病的方法。
• COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF
  申请人：PELOTON THERAPEUTICS, INC.

  公开号：US20180140569A1

  公开（公告）日：2018-05-24

  The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.

  本发明提供了治疗增殖性疾病的方法和药物组合物。该方法涉及向所述受试者施用HIF-2alpha抑制剂和免疫治疗药物的步骤。
• COMPOUNDS AND METHODS FOR TREATING CANCER
  申请人：ANTIDOTE IP HOLDINGS, LLC

  公开号：US20200299282A1

  公开（公告）日：2020-09-24

  Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.

  提供了替代肉桂酰胺化合物和类似物、制备这类化合物的方法、包含这类化合物的药物组合物和药物、以及使用这类化合物治疗、预防或改善癌症的方法。